Fundación Cardiovascular de Colombia   Report issue

Foundation Phase 2 Phase 3 Phase 4
Founded: Bucaramanga Colombia (1986)

Organization Overview

First Clinical Trial
2003
NCT00323973
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Fundacion Cardiovascular | Fundacion Cardiovascular de Colombia | Fundación Cardiovascular de Colombia | Research Institute/Fundación Cardiovascular de Colombia

Active Ingredients

Drugs in Phase 4 Trials (1)

candesartan (atacand) (1 trial)

Drugs in Phase 3 Trials (3)

bisoprolol (zebeta) (1 trial)

meglumine (1 trial)

nitric oxide (inomax) (2 trials)

Drugs in Phase 2 Trials (1)

COVID-19 convalescent plasma (1 trial)

Drugs in Other Trials (4)

dexamethasone (1 trial)

levobupivacaine (chirocaine) (1 trial)

multivitamins (1 trial)

vitamin d3 (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Cardiomyopathies (Phase 3)

Chagas Cardiomyopathy (Phase 3)

Critical Illness (Phase 2)

Diabetic Foot (Phase 3)

Foot Ulcer (Phase 3)

Glucose Intolerance (Phase 4)

Heart Failure (Phase 3)

Leishmaniasis (Phase 3)

Leishmaniasis, Cutaneous (Phase 3)

Obesity (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 9